منابع مشابه
Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates
Background: Reduction/alkylation is one of the leading strategies for the development of antibody drug conjugates (ADCs). Precise control of the reduction process would not only yield a defined number of free thiols per antibody but also result in development of more homogenous conjugates. Methods: In the present study, we investigated the effect of various dithiothreitol (DTT) concentrations, ...
متن کاملImmunomedics Creates Novel Antibody-cytokine Conjugates for Cancer Therapy
Washington, DC, April 8, 2013 --Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibodybased products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the creation of a new class of antibody-cytokine conjugates using the Company’s patented DOCK-AND-LOCKTM (DNLTM) platform technology. T...
متن کاملAntibody–drug conjugates as novel anti-cancer chemotherapeutics
Over the past couple of decades, antibody-drug conjugates (ADCs) have revolutionized the field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues upon dose escalation, ADCs utilize monoclonal antibodies (mAbs) to specifically bind tumour-associated target antigens and deliver a highly potent cytotoxic agent. The synergistic combination of mAbs conjugated to small...
متن کاملAntibody-Drug Conjugates as Novel and Potent Cancer Therapeutics
Conventional chemotherapeutic drugs to treat cancer suffers from the lack of selectivity towards the tumor site and thus causing damage to even healthy tissues. Drug dose escalation to therapeutically active levels is often impossible with chemotherapeutic drugs due to this toxicity. The selectivity of the treatment was improved with the introduction of monoclonal antibody drugs that are direct...
متن کاملDevelopment of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
A quaternary ammonium-based drug-linker has been developed to expand the scope of antibody-drug conjugate (ADC) payloads to include tertiary amines, a functional group commonly present in biologically active compounds. The linker strategy was exemplified with a β-glucuronidase-cleavable auristatin E construct. The drug-linker was found to efficiently release free auristatin E (AE) in the presen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncogene
سال: 2007
ISSN: 0950-9232,1476-5594
DOI: 10.1038/sj.onc.1210373